Trade Assembly Biosciences, Inc. - ASMB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.7644 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 16.5678 |
| Open | 16.5878 |
| 1-Year Change | 1669.55% |
| Day's Range | 15.7378 - 16.5878 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | 16.0478 | -0.3200 | -1.96% | 16.3678 | 16.5878 | 15.7378 |
| Sep 9, 2024 | 16.5678 | -0.6600 | -3.83% | 17.2278 | 17.9678 | 16.0678 |
| Sep 6, 2024 | 16.4678 | 1.1100 | 7.23% | 15.3578 | 16.7678 | 15.1178 |
| Sep 5, 2024 | 16.5278 | 0.3600 | 2.23% | 16.1678 | 17.1378 | 16.1678 |
| Sep 4, 2024 | 16.5278 | 1.5600 | 10.42% | 14.9678 | 16.6278 | 14.9678 |
| Sep 3, 2024 | 15.6578 | -0.7100 | -4.34% | 16.3678 | 16.5178 | 15.2878 |
| Aug 30, 2024 | 16.0778 | 0.0500 | 0.31% | 16.0278 | 16.6678 | 16.0078 |
| Aug 29, 2024 | 16.1278 | 0.6900 | 4.47% | 15.4378 | 16.8578 | 15.4378 |
| Aug 28, 2024 | 16.3178 | 1.0200 | 6.67% | 15.2978 | 16.5878 | 15.2978 |
| Aug 27, 2024 | 16.2078 | 0.8300 | 5.40% | 15.3778 | 16.7278 | 15.3778 |
| Aug 26, 2024 | 15.7878 | 0.9700 | 6.55% | 14.8178 | 16.0778 | 14.7878 |
| Aug 23, 2024 | 14.5778 | 0.0200 | 0.14% | 14.5578 | 14.6778 | 14.0178 |
| Aug 22, 2024 | 14.2678 | -0.6200 | -4.16% | 14.8878 | 14.9678 | 13.9878 |
| Aug 21, 2024 | 14.7278 | 0.2300 | 1.59% | 14.4978 | 15.0678 | 14.4878 |
| Aug 20, 2024 | 14.4778 | -0.3900 | -2.62% | 14.8678 | 14.8678 | 14.2178 |
| Aug 19, 2024 | 14.4678 | 0.0400 | 0.28% | 14.4278 | 14.9578 | 14.1178 |
| Aug 16, 2024 | 14.1278 | 0.0100 | 0.07% | 14.1178 | 14.4278 | 14.1178 |
| Aug 15, 2024 | 14.0178 | 0.4400 | 3.24% | 13.5778 | 14.5678 | 13.5778 |
| Aug 14, 2024 | 13.7778 | -1.0900 | -7.33% | 14.8678 | 14.8678 | 13.5678 |
| Aug 13, 2024 | 14.7178 | 2.2500 | 18.05% | 12.4678 | 14.9678 | 12.4678 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Assembly Biosciences, Inc. Company profile
About Assembly Biosciences Inc
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).
Equity composition
Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.
| Industry: | Proprietary & Advanced Pharmaceuticals |
Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com